User login
Key clinical point: Ixekizumab was more effective than adalimumab in treating signs and symptoms of psoriatic arthritis (PsA), regardless of severity of concomitant psoriasis.
Major finding: At week 52, a significantly greater proportion of patients treated with ixekizumab vs. adalimumab achieved at least 50% improvement in American College of Rheumatology criteria and 100% improvement in Psoriasis Area Severity Index simultaneously, irrespective of presence (38.8% vs. 17.6%; P = .026) or absence (39.3% vs. 28.1%; P = .014) of moderate-to-severe psoriasis at baseline.
Study details: Findings are from a post hoc analysis of the phase 3b/4 SPIRIT-H2H study including 566 patients who were biologic disease-modifying antirheumatic drugs-naive with active PsA and concomitant psoriasis. They were randomly assigned to either ixekizumab or adalimumab.
Disclosures: This study was funded by Eli Lilly and Company, Indianapolis, IN, USA. Some of the authors, including the lead author, reported ties with several sources including Eli Lilly and Company. Four authors declared being employees and shareholders of Eli Lilly and Company.
Source: Kristensen LE et al. Rheumatol Ther. 2021(Oct 28). Doi: 10.1007/s40744-021-00388-8.
Key clinical point: Ixekizumab was more effective than adalimumab in treating signs and symptoms of psoriatic arthritis (PsA), regardless of severity of concomitant psoriasis.
Major finding: At week 52, a significantly greater proportion of patients treated with ixekizumab vs. adalimumab achieved at least 50% improvement in American College of Rheumatology criteria and 100% improvement in Psoriasis Area Severity Index simultaneously, irrespective of presence (38.8% vs. 17.6%; P = .026) or absence (39.3% vs. 28.1%; P = .014) of moderate-to-severe psoriasis at baseline.
Study details: Findings are from a post hoc analysis of the phase 3b/4 SPIRIT-H2H study including 566 patients who were biologic disease-modifying antirheumatic drugs-naive with active PsA and concomitant psoriasis. They were randomly assigned to either ixekizumab or adalimumab.
Disclosures: This study was funded by Eli Lilly and Company, Indianapolis, IN, USA. Some of the authors, including the lead author, reported ties with several sources including Eli Lilly and Company. Four authors declared being employees and shareholders of Eli Lilly and Company.
Source: Kristensen LE et al. Rheumatol Ther. 2021(Oct 28). Doi: 10.1007/s40744-021-00388-8.
Key clinical point: Ixekizumab was more effective than adalimumab in treating signs and symptoms of psoriatic arthritis (PsA), regardless of severity of concomitant psoriasis.
Major finding: At week 52, a significantly greater proportion of patients treated with ixekizumab vs. adalimumab achieved at least 50% improvement in American College of Rheumatology criteria and 100% improvement in Psoriasis Area Severity Index simultaneously, irrespective of presence (38.8% vs. 17.6%; P = .026) or absence (39.3% vs. 28.1%; P = .014) of moderate-to-severe psoriasis at baseline.
Study details: Findings are from a post hoc analysis of the phase 3b/4 SPIRIT-H2H study including 566 patients who were biologic disease-modifying antirheumatic drugs-naive with active PsA and concomitant psoriasis. They were randomly assigned to either ixekizumab or adalimumab.
Disclosures: This study was funded by Eli Lilly and Company, Indianapolis, IN, USA. Some of the authors, including the lead author, reported ties with several sources including Eli Lilly and Company. Four authors declared being employees and shareholders of Eli Lilly and Company.
Source: Kristensen LE et al. Rheumatol Ther. 2021(Oct 28). Doi: 10.1007/s40744-021-00388-8.